C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

19 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

23 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

08 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

30 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

03 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

29 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

26 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04 Aug 2022 08:00:03 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors

02 Aug 2022 08:00:03 By Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

16 May 2022 08:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 May 2022 08:00:02 By Nasdaq GlobeNewswire

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

08 Apr 2022 13:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

16 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

09 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 

08 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

24 Feb 2022 07:00:03 By Nasdaq GlobeNewswire

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire